• Alnylam Pharmaceuticals EPS for the quarter ending March 31, 2025 was $-0.44, a 15.38% decline year-over-year.
• Alnylam Pharmaceuticals 2024 annual EPS was $-2.18, a 38.07% decline from 2023.
• Alnylam Pharmaceuticals 2023 annual EPS was $-3.52, a 62.15% decline from 2022.
• Alnylam Pharmaceuticals 2022 annual EPS was $-9.3, a 29.17% increase from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.